Ibio Inc (IBIO) Stock Price, Quote & News

Company Profile

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies agai...

Industry: Biotechnology

Sector: Healthcare

Phone: 979 446 0027

Website: ibioinc.com

Address:

11750 Sorrento Valley Road, Suite 200, San Diego, United States

FullThrottle1 Nov. 15 at 9:16 PM

$IBIO just another biotech scam

0 · Reply

FullThrottle1 Nov. 15 at 8:42 PM

$IBIO Next commercialized product will be the first here. Don’t hold your breath little fellas. They raise money selling more stock and burn it just as fast. Try it the old fashion way, sell a product!

0 · Reply

Dingalingading Nov. 15 at 6:41 PM

$IBIO Hi old friends👋. I'm up 200% in little over a 1 year since I left here at 1.97, saw ibio's run February🚀 but then went so far down💩. anyways, I went all in on immx at its ATL. it's turning out to be my best investment ever. the data is awesome 97% effective first in class treatment for Relapsed/Refractory AL Amyloidosis. Halfway to target so far. lots of 13F's coming in. buyout eminent. Nancy T. Chang joined the board couple months ago (led XOLAIR® from invention through FDA approval and commercialization, exceeding $5 billion in sales so far), a week ago they appointed Chief Commercial Officer Michael Grabow [Former Senior Commercial Leader Chimerix (CMRX, acquired by Jazz for $935 million) ] hope all is well. GLTA! wishing some of you were winning with me.... check out the symmetry on the 5 year at same time 2 years ago. With buyouts averaging 4,5x revenue. and immx currently at 4.30 share price. pay out 40$ a share is real possibility.

0 · Reply

suredubb Nov. 15 at 3:42 AM

$IBIO love when big investors are involved.. stock will go down at times, but they always support it.. the institutional and insider buying is enough endorsement for me.. next big analyst coverage and this stock flys… when they name a strategic partner soon… boom human trials begin in early 2027

1 · Reply

IBIO_KEVINTL Nov. 15 at 1:36 AM

$IBIO I think I will be here for a while. Selling candles and buying back dips. Smart money is here as well

0 · Reply

CompoundCowboy Nov. 15 at 1:07 AM

$IBIO

1 · Reply

2pumps1dump Nov. 14 at 9:17 PM

$IBIO

0 · Reply

vikingpurple Nov. 14 at 8:44 PM

$IBIO Coming up on 15 years of ownership in the stock. It’s not a pretty sight doing a review.

1 · Reply

Chyeahhh Nov. 14 at 8:02 PM

$IBIO didn’t get the move I got long early and got out at 1.24 from 1.18 . Needed to feed up liquidity and I told myself that Friday event thing may be a sell the news. But no it went for a nice move past 1.5 I think. With all the market action bearish lately to look at a chart and it be back to where I got it is supportive of bullish strength. But I think I’ll risk staying on the side again because I need to see more moves to determine if this isn’t dilution of this is strength and Demand supporting the constant cash burn. We will see or this will trade back lower or start to melt from here with later more parabolic vs rate of time move.

1 · Reply

2pumps1dump Nov. 14 at 7:30 PM

$IBIO 2 more 13G’s, they’re playing you fools. Added.

0 · Reply

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

Oct 30, 2025, 7:00 AM EDT - 16 days ago

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

Oct 23, 2025, 7:00 AM EDT - 23 days ago

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 21, 2025, 7:00 AM EDT - 25 days ago

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

Sep 5, 2025, 7:30 AM EDT - 2 months ago

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Aug 25, 2025, 7:00 AM EDT - 2 months ago

iBio Announces Closing of $50 Million Public Offering

Aug 19, 2025, 8:01 AM EDT - 3 months ago

iBio Announces Pricing of $50 Million Public Offering

Aug 18, 2025, 4:01 PM EDT - 3 months ago

iBio Announces Proposed Public Offering

Jun 24, 2025, 7:00 AM EDT - 5 months ago

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

Jun 23, 2025, 4:15 PM EDT - 5 months ago

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

Jun 16, 2025, 7:00 AM EDT - 5 months ago

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

May 5, 2025, 8:00 AM EDT - 6 months ago

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

May 2, 2025, 8:00 AM EDT - 7 months ago

iBio Reports Fiscal Third Quarter 2025 Financial Results

Apr 29, 2025, 1:43 PM EDT - 7 months ago

iBio Raises $6.2 Million Through Warrant Inducement Transaction

Apr 22, 2025, 8:00 AM EDT - 7 months ago

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

Apr 7, 2025, 7:00 AM EDT - 7 months ago

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Feb 19, 2025, 4:05 PM EST - 9 months ago

iBio to Begin Trading on the Nasdaq Stock Exchange

Feb 10, 2025, 4:05 PM EST - 9 months ago

iBio Reports Fiscal Second Quarter 2025 Financial Results

Jan 2, 2025, 7:00 AM EST - 11 months ago

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

Nov 12, 2024, 4:05 PM EST - 1 year ago

iBio Reports Fiscal First Quarter 2025 Financial Results

Sep 20, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sep 3, 2024, 7:00 AM EDT - 1 year ago

iBio to Participate in Upcoming Investor Conferences

Aug 12, 2024, 4:30 PM EDT - 1 year ago

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

Jun 3, 2024, 7:00 AM EDT - 1 year ago

iBio Closes Sale of Manufacturing Facility in Texas

May 13, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

Mar 27, 2024, 2:43 PM EDT - 1 year ago

iBio stock nearly tripled on Wednesday: here's why

Mar 27, 2024, 7:00 AM EDT - 1 year ago

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

Mar 26, 2024, 7:35 PM EDT - 1 year ago

iBio Announces $15.0 Million Private Placement

Feb 26, 2024, 7:45 AM EST - 1 year ago

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

Jan 16, 2024, 8:15 AM EST - 1 year ago

iBio Announces Participation in 23rd Annual PepTalk Conference

Jan 16, 2024, 6:50 AM EST - 1 year ago

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

ALVR GRI VYNE

Dec 26, 2023, 7:15 AM EST - 2 years ago

iBio Amends and Extends Maturity of Credit Agreement

Dec 5, 2023, 8:00 AM EST - 2 years ago

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

Nov 27, 2023, 5:20 PM EST - 2 years ago

iBio Announces Reverse Stock Split

Nov 1, 2023, 8:24 AM EDT - 2 years ago

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

Oct 2, 2023, 6:45 AM EDT - 2 years ago

iBio Explains Recent Filing of Registration Statement

Sep 27, 2023, 4:19 PM EDT - 2 years ago

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

Sep 21, 2023, 4:05 PM EDT - 2 years ago

iBio Announces Amendment to Credit Agreement with Woodforest

Aug 14, 2023, 4:15 PM EDT - 2 years ago

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

Jun 27, 2023, 8:00 AM EDT - 2 years ago

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

Jun 12, 2023, 4:15 PM EDT - 2 years ago

iBio Forges Research Collaboration with the National Institutes of Health

May 9, 2023, 4:30 PM EDT - 2 years ago

iBio to Participate in the JMP Securities Life Sciences Conference

Apr 4, 2023, 4:05 PM EDT - 2 years ago

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

Mar 31, 2023, 8:10 AM EDT - 2 years ago

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

Feb 16, 2023, 4:48 PM EST - 2 years ago

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

Dec 9, 2022, 4:05 PM EST - 3 years ago

iBio Announces Closing of $3.5 Million Underwritten Public Offering

Dec 6, 2022, 11:27 PM EST - 3 years ago

iBio Announces Pricing of $3.5 Million Underwritten Public Offering

Dec 6, 2022, 4:01 PM EST - 3 years ago

iBio Announces Proposed Underwritten Public Offering

Dec 5, 2022, 8:00 AM EST - 3 years ago

iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022

Dec 2, 2022, 4:30 PM EST - 3 years ago

iBio Announces CEO Departure

FullThrottle1 Nov. 15 at 9:16 PM

$IBIO just another biotech scam

0 · Reply

FullThrottle1 Nov. 15 at 8:42 PM

0 · Reply

Dingalingading Nov. 15 at 6:41 PM

0 · Reply

suredubb Nov. 15 at 3:42 AM

1 · Reply

IBIO_KEVINTL Nov. 15 at 1:36 AM

$IBIO I think I will be here for a while. Selling candles and buying back dips. Smart money is here as well

0 · Reply

CompoundCowboy Nov. 15 at 1:07 AM

$IBIO

1 · Reply

2pumps1dump Nov. 14 at 9:17 PM

$IBIO

0 · Reply

vikingpurple Nov. 14 at 8:44 PM

$IBIO Coming up on 15 years of ownership in the stock. It’s not a pretty sight doing a review.

1 · Reply

Chyeahhh Nov. 14 at 8:02 PM

1 · Reply

2pumps1dump Nov. 14 at 7:30 PM

$IBIO 2 more 13G’s, they’re playing you fools. Added.

0 · Reply

IBIO_KEVINTL Nov. 14 at 3:54 PM

$IBIO They pushed all you rookies Out. Keep chomping at the bit! Add

0 · Reply

IBIO_KEVINTL Nov. 14 at 3:14 PM

$IBIO Come on little women

0 · Reply

suredubb Nov. 14 at 3:03 PM

$IBIO bought 14,300 more at open.. 54,013 total time to relax and let IBIO do the work

1 · Reply

IBIO_KEVINTL Nov. 14 at 2:41 PM

$IBIO Lots are buying off this bottom. Before she pops and it’s too late

0 · Reply

Rower5oh Nov. 14 at 12:49 PM

$IBIO Bought more this morning. All I know is that this company is worth a lot more than the current market cap

0 · Reply

IBIO_KEVINTL Nov. 14 at 12:33 PM

$IBIO Shes going to bounce off this bottom. I see this before The technical point up 👆

0 · Reply

IBIO_KEVINTL Nov. 14 at 12:31 PM

$IBIO That’s how you do it As long as they don’t RS you will be fine. You need nuts 🥜 in this game.

0 · Reply

2pumps1dump Nov. 14 at 11:47 AM

$IBIO 13G out, I’m loading more down here!

0 · Reply

Bigbut Nov. 14 at 2:58 AM

$IBIO beep beep beep Now’s the time If you seen my post, you know what that means If you’ve never seen my posts, the BUT stands for back up the truck

1 · Reply

flawlesssqueeze Nov. 14 at 12:20 AM

$IBIO strong FP&A is healthy!

0 · Reply

FullThrottle1 Nov. 13 at 10:52 PM

$IBIO Forever a penny stock….cant stop laughing at the lack of success here.

1 · Reply

reces1 Nov. 13 at 10:35 PM

$IBIO Waiting on $1.00. Management will get us there!

1 · Reply

Market Cap	26.09M
Revenue (ttm)	400,000.00
Net Income (ttm)	-18.38M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,595.00%
Debt to Equity Ratio	0.06

Volume	821,800
Avg Vol	3,702,962
Day's Range	N/A - N/A
Shares Out	22.49M
Stochastic %K	9%
Beta	0.93
Analysts	Strong Sell
Price Target	$3.65